SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
ADAP
--
0.00%
--
Adaptimmune Therapeutics shares are trading higher after the company late Thursday reported it was granted access to priority medicines regulatory support by EMA for ADP-A2M4 for treatment of Synovial Sarcoma. UPDATE: Shares have since reversed.
Benzinga · 07/24 14:01
Adaptimmune Therapeutics shares are trading higher after the company reported it was granted access to priority medicines regulatory support by EMA for ADP-A2M4 for treatment of Synovial Sarcoma.
Benzinga · 07/23 20:12
Adaptimmune's ADP-A2M4 nabs accelerated review in EU for soft tissue cancer
Seeking Alpha - Article · 07/23 20:10
Adaptimmune Therapeutics reports Was Granted Access To PRIority MEdicines Regulatory Support By EMA For ADP-A2M4 For Treatment Of Synovial Sarcoma
Benzinga · 07/23 20:00
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative
GlobeNewswire · 07/23 20:00
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. marke
GlobeNewswire · 07/22 12:00
Should You Buy Adaptimmune Therapeutics plc (ADAP)?
Insider Monkey · 07/05 19:25
Edited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMT
Q1 2020 Adaptimmune Therapeutics PLC Earnings Call
Thomson Reuters StreetEvents · 06/23 15:26
Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?
Zacks · 06/17 14:33
How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong Industry
Zacks · 06/17 13:52
Is Adaptimmune Therapeutics a Buy?
Motley Fool · 06/12 11:30
Why Adaptimmune Therapeutics Stock Crushed It in May
Motley Fool · 06/08 15:30
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
GlobeNewswire · 06/04 15:45
Adaptimmune Therapeutics shares are trading higher after the company priced a 20.5 million ADS offering at $11 per ADS.
Prices 20.5M ADS Offering @$11/ADS
Benzinga · 06/02 13:06
Adaptimmune prices ADS offering at $11
Adaptimmune Therapeutics (NASDAQ:ADAP) has priced its public offering of 20.5M American Depositary Shares (“ADSs”) at $11.00/ADS, for expected gross procee
seekingalpha · 06/02 13:00
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1)
Benzinga · 06/02 11:45
Adaptimmune Therapeutics Prices 20.5M ADS Offering @$11/ADS
Adaptimmune Therapeutics plc ("Adaptimmune")(NASDAQ: ADAP) announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares ("ADSs") at a price to the public of $11.00 per ADS.
Benzinga · 06/02 09:38
Adaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTD
SmarterAnalyst · 06/02 09:37
Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?
Zacks · 06/02 05:38
Why Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded Today
Motley Fool · 06/01 17:51